FI87197B - Foerfarande foer framstaellning av terapeutiskt aktiva fenylkarbamater. - Google Patents

Foerfarande foer framstaellning av terapeutiskt aktiva fenylkarbamater. Download PDF

Info

Publication number
FI87197B
FI87197B FI860914A FI860914A FI87197B FI 87197 B FI87197 B FI 87197B FI 860914 A FI860914 A FI 860914A FI 860914 A FI860914 A FI 860914A FI 87197 B FI87197 B FI 87197B
Authority
FI
Finland
Prior art keywords
compounds
compound
physostigmine
formula
administered
Prior art date
Application number
FI860914A
Other languages
English (en)
Finnish (fi)
Other versions
FI87197C (sv
FI860914A0 (fi
FI860914A (fi
Inventor
Michael Chorev
Zeev Tashma
Rosin Marta Weinstock
Original Assignee
Proterra Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11055728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI87197(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Proterra Ag filed Critical Proterra Ag
Publication of FI860914A0 publication Critical patent/FI860914A0/fi
Publication of FI860914A publication Critical patent/FI860914A/fi
Application granted granted Critical
Publication of FI87197B publication Critical patent/FI87197B/fi
Publication of FI87197C publication Critical patent/FI87197C/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/14—Dithiocarbamic acids; Derivatives thereof
    • C07C333/30—Dithiocarbamic acids; Derivatives thereof having sulfur atoms of dithiocarbamic groups bound to other sulfur atoms
    • C07C333/32—Thiuramsulfides; Thiurampolysulfides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Claims (6)

1. Förfarande för framställning av en tera-peutiskt aktiv förening med den allmänna formeln 1' eller dess farmaceutiskt godtagbara syraadditionssalt, 15 0 Il /Ri rS (SU /C„3 " 20 -Νζ l XcH3 ch3 varvid Rx är väte, lägre alkyl, som är nägon annan än 25 metyl cyklohexyl eller allyl; R2 är väte, metyl eller etyl; eller R1 och R2 tillsammans med kväve, tili vilket de är bundna, bildar en morfolinoradikal; ; känne-t e c k n a t därav, att en förening med formeln II, 30 ^ (SXLh<cH3 ] X ch3 35 c«3 29 87 1 97 amideras och att den härvid bildade föreningen med formel I* tas till vara i fri basform eller i form av ett farmakologiskt godtagbart salt.
2. Förfarande enligt patenrkrav 1 för frams-5 tällning av en förening med formel I', varvid R2 är väte, kännetecknat därav, att en förening med formel II tilläts reagera med en isocyanat.
3. Förfarande enligt patentkrav 1, k ä n n e t e c k n a t därav, att en förening med formel II 10 tilläts reagera med en karbamoylhalogenid.
4. Förfarande enligt patentkrav 3, kännetecknat därav, att en förening med formel II tilläts reagera med en karbamoylklorid.
FI860914A 1985-03-05 1986-03-04 Förfarande för framställning av terapeutiskt aktiva fenylkarbamater FI87197C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL7449785 1985-03-05
IL74497A IL74497A (en) 1985-03-05 1985-03-05 Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives

Publications (4)

Publication Number Publication Date
FI860914A0 FI860914A0 (fi) 1986-03-04
FI860914A FI860914A (fi) 1986-09-06
FI87197B true FI87197B (fi) 1992-08-31
FI87197C FI87197C (sv) 1992-12-10

Family

ID=11055728

Family Applications (1)

Application Number Title Priority Date Filing Date
FI860914A FI87197C (sv) 1985-03-05 1986-03-04 Förfarande för framställning av terapeutiskt aktiva fenylkarbamater

Country Status (25)

Country Link
US (1) US4948807A (sv)
EP (1) EP0193926B3 (sv)
JP (1) JPS61225158A (sv)
KR (1) KR940010764B1 (sv)
AT (1) ATE58130T1 (sv)
AU (1) AU595504B2 (sv)
CA (1) CA1284501C (sv)
CY (2) CY1748A (sv)
DE (2) DE3675408D1 (sv)
DK (1) DK172851B1 (sv)
ES (1) ES8801193A1 (sv)
FI (1) FI87197C (sv)
GR (1) GR860586B (sv)
HK (1) HK130293A (sv)
HU (1) HU201297B (sv)
IE (1) IE58838B1 (sv)
IL (1) IL74497A (sv)
LU (1) LU90312I2 (sv)
MY (1) MY137602A (sv)
NL (1) NL980031I2 (sv)
NZ (1) NZ215348A (sv)
PH (1) PH23325A (sv)
PL (1) PL146301B1 (sv)
PT (1) PT82127B (sv)
ZA (1) ZA861653B (sv)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667001A5 (de) * 1985-09-03 1988-09-15 Hugo Degen Untermatratze.
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US5091583A (en) * 1990-05-07 1992-02-25 Air Products And Chemicals, Inc. Tertiary amine catalysts for polurethanes
IT1271679B (it) * 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
DK0951284T3 (da) * 1996-12-18 2004-02-16 Teva Pharma Phenylethylminderivater
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
DE69732984T2 (de) 1996-12-18 2006-02-16 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
WO1998031356A1 (en) * 1997-01-17 1998-07-23 Takeda Chemical Industries, Ltd. Idebenone containing combination agent for treating alzheimer's disease
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
US7939522B1 (en) * 1998-11-23 2011-05-10 Bonnie M Davis Dosage formulations for acetylcholinesterase inhibitors
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) * 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
EP1251744B2 (en) 2000-01-28 2015-08-26 DSM IP Assets B.V. Enhanced production of lipids containing polyenoic fatty acids by high density cultures of eukaryotic microbes in fermentors
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
WO2001066114A1 (en) * 2000-03-03 2001-09-13 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
AU2003263574A1 (en) * 2002-05-31 2003-12-19 Patel, Hetalkumar, Virendrabhai A process for the preparation of phenylcarbamates
SI2389937T1 (sl) 2002-06-14 2018-10-30 Toyama Chemical Co., Ltd, Farmacevtska sestava za izboljšanje možganske funkcije
US7176201B2 (en) * 2002-10-07 2007-02-13 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis
CZ20023555A3 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
DE10301851A1 (de) * 2003-01-17 2004-07-29 Lts Lohmann Therapie-Systeme Ag Verfahren zur medikamentösen Prophylaxe gegen Vergiftungen durch Cholinesterase-Hemmer, sowie hierfür geeignete Wirkstoffe und Arzneimittel
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
WO2005042475A2 (en) * 2003-10-21 2005-05-12 Sention, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
ES2347152T3 (es) 2003-11-26 2010-10-26 Pfizer Products Inc. Derivados de aminopirazol como inhibidores de gsk-3.
GB0329284D0 (en) * 2003-12-18 2004-01-21 Avecia Ltd Process
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006050359A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
KR101168211B1 (ko) * 2004-11-08 2012-07-25 엠큐어 파마슈티컬즈 리미티드 （ｓ）－３－［（１－디메틸아미노）에틸］－페닐－ｎ－에틸－ｎ－메틸－카바메이트의 제조를 위한 효과적인 방법
CA2590533C (en) * 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
BRPI0620659A2 (pt) * 2005-12-09 2017-10-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2007127474A2 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
ATE472523T1 (de) * 2006-08-17 2010-07-15 Alembic Ltd Verbessertes verfahren zur herstellung von rivastigmin
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
MX2009004516A (es) 2006-10-27 2009-08-12 Medivation Neurology Inc Metodos y terapias de combinacion para tratar enfermedad de alzheimer.
JP2010518010A (ja) * 2007-02-02 2010-05-27 コルシド・ファーマシューティカルズ・インコーポレイテッド コリンエステラーゼを阻害する化合物
US8013181B2 (en) 2007-04-10 2011-09-06 Dr. Reddy's Laboratories Limited Preparation of rivastigmine and its salts
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
US20090048229A1 (en) * 2007-07-18 2009-02-19 Rupniak Nadia M J Methods for promoting wakefulness
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US8420846B2 (en) 2008-08-25 2013-04-16 Jubilant Life Sciences Limited Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
US8247405B2 (en) 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
CN101580482B (zh) * 2009-05-27 2014-04-23 沈阳药科大学 一种重酒石酸盐卡巴拉汀的制备方法和应用
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CN102134206B (zh) * 2010-01-27 2013-11-20 上海京新生物医药有限公司 一种卡巴拉汀的制备方法
WO2011100373A1 (en) * 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
US8852900B2 (en) 2010-06-17 2014-10-07 Codexis, Inc. Biocatalysts and methods for the synthesis of (S)-3-(1-aminoethyl)-phenol
WO2012131699A1 (en) 2011-03-30 2012-10-04 Neon Laboratories Ltd. Process for preparation of highly pure 3-dimethylaminophenyl dimethylcarbamate
CN102786441B (zh) * 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
CA2870303A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Organic compounds
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
CA2921308A1 (en) 2013-08-16 2015-02-19 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) * 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
US2208485A (en) * 1937-04-24 1940-07-16 Hoffmann La Roche Process for the manufacture of disubstituted carbamic acid esters of phenols containing a basic substituent
US2362508A (en) * 1940-12-06 1944-11-14 Merck & Co Inc Therapeutic substances
US2493710A (en) * 1947-03-21 1950-01-03 Hoffmann La Roche Carbamic acid esters
DE1037753B (de) * 1956-07-13 1958-08-28 Rohm & Haas Schaedlingsbekaempfungsmittel

Also Published As

Publication number Publication date
EP0193926A3 (en) 1987-05-13
ZA861653B (en) 1987-10-28
EP0193926B1 (en) 1990-11-07
GR860586B (en) 1986-07-07
IE860558L (en) 1986-09-05
PH23325A (en) 1989-07-14
ES552627A0 (es) 1988-01-01
HU201297B (en) 1990-10-28
AU5428486A (en) 1986-09-11
CA1284501C (en) 1991-05-28
FI87197C (sv) 1992-12-10
HUT41718A (en) 1987-05-28
FI860914A0 (fi) 1986-03-04
AU595504B2 (en) 1990-04-05
DE3675408D1 (de) 1990-12-13
NZ215348A (en) 1990-04-26
LU90312I2 (fr) 1999-01-06
CY2004004I2 (el) 2009-11-04
NL980031I1 (nl) 1999-01-04
FI860914A (fi) 1986-09-06
ES8801193A1 (es) 1988-01-01
EP0193926B3 (en) 2010-04-28
KR860007207A (ko) 1986-10-08
DK172851B1 (da) 1999-08-16
EP0193926A2 (en) 1986-09-10
MY137602A (en) 2009-02-27
DK99186A (da) 1986-09-06
IL74497A (en) 1990-02-09
DK99186D0 (da) 1986-03-04
JPS61225158A (ja) 1986-10-06
NL980031I2 (nl) 1999-03-01
JPH0255416B2 (sv) 1990-11-27
KR940010764B1 (ko) 1994-11-11
PL146301B1 (en) 1989-01-31
PT82127B (pt) 1988-07-01
IE58838B1 (en) 1993-11-17
US4948807A (en) 1990-08-14
HK130293A (en) 1993-12-03
CY1748A (en) 1994-06-03
PT82127A (en) 1986-04-01
CY2004004I1 (el) 2009-11-04
ATE58130T1 (de) 1990-11-15
IL74497A0 (en) 1985-06-30
DE19875046I1 (de) 2003-09-04

Similar Documents

Publication Publication Date Title
FI87197B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva fenylkarbamater.
US6211360B1 (en) Ibogamine congeners
CA1211435A (en) N-phenyl-n&#39;-cycloalkyl-alkenoyl piperazines and process for producing same
DE60107435T2 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
SK3612000A3 (en) Sustained release tablet formulation to treat parkinson disease
US6916823B2 (en) Method of treatment of dopamine-related dysfunction
AU780738B2 (en) Novel methods for the treatment and prevention of ileus
MX2008007687A (es) Compuestos y métodos para inhibir la interacción de proteínas bcl con compañeros enlazantes.
US20220175700A1 (en) Visual cycle modulators
US5712269A (en) M2 receptor ligand for the treatment of neurological disorders
WO1996031470A1 (en) Novel heterocyclic compounds
EP3283457A1 (en) Compounds and methods for the treatment of neurodegenerative diseases
AU2004275852A1 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
RU2300532C2 (ru) Производные бензо[g]хинолина для лечения глаукомы и близорукости, способ их получения и фармацевтическая композиция
EP1011676B1 (en) Quinoline-urea derivatives for the treatment of withdrawal syndrome and withdrawal-induced brain damage
US6962930B1 (en) Compounds, compositions and method suitable for amelioration of withdrawal syndromes and withdrawal-induced brain damage
EP1192161B1 (en) Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands
WO1996031500A1 (en) Novel heterocyclic compounds
SU1517759A3 (ru) Способ получени 4-амино-2-(2-бутанон-3-ил)-окси-5-хлор-N-[2-(диэтиламино)этил]бензамида или его солей
EP0820443B1 (en) Heterocyclic compounds for treating diabetes
US6908915B1 (en) Tricyclic compounds and their uses as antiarrhythmic antifibrillatory and defibrillatory agents
US3976771A (en) Glycylglycine amide preparations and method of use antiarrhythmic
PT100133B (pt) Agentes neuroprotectores a base de derivados de iminometano-dibenzo{a,d}ciclo-hepteno, composicoes que os contem, sua utilizacao e processo para a sua preparacao
WO1996031479A1 (en) Novel heterocyclic compounds
WO1996031482A1 (en) Novel heterocyclic compounds

Legal Events

Date Code Title Description
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L152

Extension date: 20110303

FG Patent granted

Owner name: PROTERRA AG

MA Patent expired